Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
Biomarkers - Dates - Meeting September 2005 -

Manchester, September 9th 2005

Programme

11:00 – 11:15
INTRODUCTION
Dr. Sarah Tabrizi
A brief overview of biomarkers in Huntington’s disease andwhat constitutes the ideal biomarker.

11:15 –11:30
Presentations on Non-imaging Biomarkers Approaches in Huntington’s disease
Nature and Progress of the High Q Sponsored Biomarkers Projects.
Allan Tobin, High Q Foundation

11:30 –11:45
Metabonomic Approaches to Identification of Biomarkers in Huntington’s disease.
Elaine Holmes, Imperial College, London

11:45 – 12:00
Cambridge HD Researchers’ Approaches to Identification of Biomarkers in HD
Andrew Michel, University of Cambridge
12:00 – 12:15
Identification of CSF orexin levels as a biomarker for Huntington’s disease.
Asa Peterson, Lund University, Sweden

12:15- 12:30
Abnormalities of the HPA Axis in Huntington’s disease.
Maria Bjorkqvist, Lund University, Sweden

12:30 – 12:45
Epigenetic Gene Control Mechanisms in the Development and Progression of Huntington’s disease – how this may be useful in identification of biomarkers in Huntington’s disease.
Pernette Verschure, University of Amsterdam, NDL

LUNCH
Approx time for buffet lunch

13.15 – 13.30

Tracking Biomarkers in Mouse Pre-clinical Trials
Gillian Bates, King’s College London

13.30-13.45
Proteomic markers of Neurodegeneration in mouse models of disease.
Claus Zabel, University of Berlin
 
13.45-14.00
Proteomic Approaches to Biomarker Identification in Huntington’s disease, and how interlinking current studies with HD imaging studies is important
Sarah Tabrizi, Institute of Neurology, London

14.00-14.15
Using the Best-Balance Constraint Procedure (BBCP) in the interpretation of HD microarray data across species: preliminary results
Christian Neri, Department of Genomic Biology, Inserm, Paris

14.15-14.30
Microarray Approaches to Biomarker Identification to HD I
Angela Hodges, University of Cardiff

14.30-14.45
Microarray Approaches to Biomarker Identification to HD II
Ruth Luthi-Carter,University of Lausanne

14.45-15.15
Group Discussion
on recent papers
Strand et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker.
Hum Mol Genet. 2005 Jul 1;14(13):1863-76.
Borovecki et al Proc Natl Acad Sci U S A. 2005 Aug
2;102(31):11023-8.
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.

These will be discussed by the whole working party but will be led by Ruth Luthi-Carter, Angela Hodges and Lesley Jones, all who have expertise in array approaches. They will evaluate these two papers and we will all discuss how the data should be validated.

15.15-16.00
Over coffee
General Group
Discussion
  • Collection of Samples within Euro-HD – blood, urine, muscle and CSF and validation of small studies – how to move forward
  • Comparing the use of imaging with the wet biomarkers approach
  • How to take forward identification of Biomarkers within the Euro- HD consortium.